In the DB phase , 183 of 305 patients ( 62 % with 3-month paliperidone palmitate ; 58 % with placebo ) had at least 1 treatment-emergent adverse event ; those noted more frequently in the group receiving paliperidone palmitate than in the placebo group were headache ( 9 % vs 4 % ) , weight increased ( 9 % vs 3 % ) , nasopharyngitis ( 6 % vs 1 % ) , and akathisia ( 4 % vs 1 % ) .